Accretion Pharmaceuticals
ACCPL NSE
Accretion Pharmaceuticals
HealthcareNSE: ACCPL Pharmaceuticals
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹233 Cr
Volatility
Moderate
P/E Ratio
24.1
EBITDA
₹14.95 Cr
Return on Equity
44.44%
Debt to Equity
0.23
Book Value
₹49.21
52W High
₹214.7
52W Low
₹53.8
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has a good return on equity (ROE) track record: 3 Years ROE 35.3%
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
Growth Rate
Revenue Growth
55.88% lower than
3Y
Net Income Growth
43.24% lower than
3Y
Cash Flow Change
150% higher than
3Y
ROE
63.5% higher than
3Y
ROCE
249% level than
3Y
EBITDA Margin (Avg.)
-20.15% lower than
3Y
Quarterly Results
| Particulars | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 13.35 | 18.56 | 38.81 | 43.74 | 45.89 |
| Expenses | 10.78 | 14.23 | 31.27 | 36.67 | 38.01 |
| Operating Profit | 2.57 | 4.33 | 7.54 | 7.07 | 7.88 |
| OPM % | 19.25% | 23.33% | 19.43% | 16.16% | 17.17% |
| Other Income | 0.05 | 0.02 | 0.08 | 0.11 | 0.08 |
| Interest | 0.4 | 0.69 | 0.74 | 0.37 | 0.48 |
| Depreciation | 0.22 | 0.37 | 0.41 | 0.4 | 0.81 |
| PBT | 2 | 3.29 | 6.47 | 6.41 | 6.67 |
| Tax % | 25% | 25.23% | 33.08% | 25.9% | 26.24% |
| Net Profit | 1.49 | 2.46 | 4.33 | 4.75 | 4.92 |
| EPS in Rs | 3.72 | 3.01 | 5.3 | 4.27 | 4.43 |
Profit & Loss
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 13.35 | 57.38 | 89.63 |
| Expenses | 10.78 | 45.49 | 74.68 |
| Operating Profit | 2.57 | 11.89 | 14.95 |
| OPM % | 19.25% | 20.72% | 16.68% |
| Other Income | 0.05 | 0.09 | 0.19 |
| Interest | 0.4 | 1.44 | 0.85 |
| Depreciation | 0.22 | 0.77 | 1.21 |
| PBT | 2 | 9.77 | 13.08 |
| Tax % | 25% | 30.4% | 26.15% |
| Net Profit | 1.49 | 6.79 | 9.67 |
| EPS in Rs | 3.72 | 8.31 | 8.7 |
| Div. Payout % | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity Capital | 4 | 8.17 | 11.12 |
| Reserves | 1.49 | 7.12 | 43.59 |
| Borrowings | 13.48 | 14.1 | 12.32 |
| Other Liabilities | 8.47 | 10.48 | 9.63 |
| Total Liabilities | 27.44 | 39.87 | 76.66 |
| Fixed Assets | 5.25 | 6.09 | 13.21 |
| CWIP | 0 | 0 | 0.2 |
| Investments | 0 | 0 | 0 |
| Other Assets | 22.19 | 33.78 | 63.25 |
| Total Assets | 27.44 | 39.87 | 76.66 |
Cash Flow
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Operating | -11.51 | 5.75 | -14.62 |
| Investing | -5.48 | -1.61 | -8.53 |
| Financing | 17.08 | -4.18 | 27.12 |
| Net Cash Flow | 0.09 | -0.04 | 3.97 |
| Free Cash Flow | -16.99 | 4.14 | -23.15 |
| CFO/OP | -479 | 64 | -75 |
Ratios
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Debtor Days | 159 | 74.17 | 91.22 |
| Inventory Days | 564 | 188 | 159 |
| Days Payable | 256 | 69.41 | 32.32 |
| Cash Conversion Cycle | 466 | 193 | 218 |
| Working Capital Days | 189 | 65.33 | 146 |
| ROCE % | — | 46.36% | 28.89% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Accretion Pharmaceuticals insights
57 extracted metrics + investor summaries across FY22–FY26.
Documents
1
Copy of Newspaper Publication
10 Sep - Postal ballot notice dispatched electronically on 9 September 2026; e-voting runs 10 September-9 October 2026. 10 Sep - Postal ballot notice dispatched electronically on 9 September 2026; e-voting runs 10 September-9 October 2026.
2
Shareholders meeting
9 Sep - Postal ballot opens 10 Sep-9 Oct 2026 for MOA alteration, ₹500 crore borrowing limit, and security approvals. 9 Sep - Postal ballot opens 10 Sep-9 Oct 2026 for MOA alteration, ₹500 crore borrowing limit, and security approvals.
3
General Updates
1 Sep - Board approved MOA object clause change and higher borrowing, security, loan and investment limits via postal ballot. 1 Sep - Board approved MOA object clause change and higher borrowing, security, loan and investment limits via postal ballot.
4
Amendment to AOA/MOA
1 Sep - Board approved object clause change, higher borrowing limits, and loans/guarantees subject to postal ballot. 1 Sep - Board approved object clause change, higher borrowing limits, and loans/guarantees subject to postal ballot.
5
Shareholders meeting
27 Aug - 3rd AGM held on 27 Aug 2026; financials adopted and Hardik Prajapati offered for reappointment. 27 Aug - 3rd AGM held on 27 Aug 2026; financials adopted and Hardik Prajapati offered for reappointment.
Frequently Asked Questions about Accretion Pharmaceuticals
What does Accretion Pharmaceuticals Ltd do?
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.[1]
Where is Accretion Pharmaceuticals Ltd (ACCPL) listed?
Accretion Pharmaceuticals Ltd trades as ACCPL on the NSE.
Which sector does Accretion Pharmaceuticals Ltd belong to?
Accretion Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Accretion Pharmaceuticals Ltd?
Accretion Pharmaceuticals Ltd has a market capitalisation of ₹233.44 Cr, which places it in the Small Cap band.
What is the PE ratio of Accretion Pharmaceuticals Ltd?
Accretion Pharmaceuticals Ltd trades at a PE ratio of 24.10, against a book value of ₹49.21 per share.
What is the 52-week high and low of Accretion Pharmaceuticals Ltd?
Over the last 52 weeks Accretion Pharmaceuticals Ltd has traded between ₹53.8 and ₹214.7.
What is the Return on Equity (ROE) of Accretion Pharmaceuticals Ltd?
Accretion Pharmaceuticals Ltd reported a return on equity of 44.44%. Its debt-to-equity ratio is 0.23.
Company Information
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ACCPL.md for Accretion Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.